Genesis Therapeutics, Inc.

Industry

  • Digital Health
    • Artificial Intelligence
  • Biotechnology
    • Drug Discovery Technologies
      • ADMET
  • Pharmaceuticals
See more in Biomedtracker

Latest on Genesis Therapeutics, Inc.

Scrip

Deal Watch: FTC Keeps Current Merger Guidelines In Place, For Now

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Trump Appointee Ferguson Keeps Biden-E

Scrip

Eight Recent Deals Tapping AI/ML For R&D

 
• By Joseph Haas

As the improvements made possible with artificial intelligence and machine learning for biopharmaceutical research and development become clear, deal making in the space has skyrocketed. S&P Global pr

Scrip

Asia Deal Watch: EpimAb Licenses Bispecific Antibody To Newly Formed Vignette

 
• By Joseph Haas, Dexter Jie Yan, Xu Hu, and Lisa Takagi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Vignette Gets Rights To BCMA×CD3 Bispec

Scrip

Finance Watch: October Begins With A VC Mega-Round For Newly Named Iambic

 
• By Mandy Jackson

Iambic Therapeutics is the latest biopharmaceutical company to raise a venture capital mega-round in support of an artificial intelligence-powered drug discovery platform and emerging clinical-stage